Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • In this phase I trial of patients with metastatic RCC, the combination of sunitinib and bevacizumab caused a high degree of hypertension and vascular and hematologic toxicities at the highest dose level. We do not plan to pursue additional study of this regimen at these doses in patients with RCC.

publication date

  • March 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3655420

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.19.0108

PubMed ID

  • 19224847

Additional Document Info

start page

  • 1432

end page

  • 9

volume

  • 27

number

  • 9